The 100-Point Mushroom Wellness Transparency Score evaluates the public-facing disclosure of mushroom wellness product pages across ten dimensions — 10 points each, 100 points total. Every dimension carries equal weight: each addresses a distinct consumer protection need, and a failure in any one of them leaves consumers without information they need to make a safe, informed decision. This article contains the complete methodology as applied in the 2026 101-entry audit.
Education-only orientation. This is not medical, legal, dosing, sourcing, purchasing, or product-use advice. It does not tell readers where or how to obtain any substance. The page reviews public-facing transparency signals and consumer-information standards only.
What this page does and does not contain. This page discusses labeling, testing visibility, ingredient disclosure, claim restraint, and public-facing safety language. It does not evaluate product effectiveness, recommend products, verify product contents, or make legal conclusions about any brand.
- Transparency score
- A public-facing signal score derived from visible consumer-facing information — not a product quality or safety certification.
- COA visibility
- How easily a consumer can find current, relevant, batch-specific lab documentation before purchase.
- Claim restraint
- Whether marketing language avoids unsupported disease-treatment or guaranteed-outcome claims.
- Disclosure clarity
- Whether legality, age limits, ingredients, and safety boundaries are stated plainly on the public product page.
Affiliation and scoring disclosure. iMicrodosing.org is an education-focused property. iMicrodosing.com is an affiliated eCommerce property and is included in this audit for transparency. Its score was calculated using the same public-facing criteria applied to other entries. Inclusion does not turn this report into a product recommendation, safety certification, legal conclusion, or verification of product contents.
Scope and limitation. This score evaluates only publicly visible information. It does not evaluate product quality, clinical safety, manufacturing standards, or legal compliance. A high score means the page communicates clearly; a low score means the page leaves consumers without information they need. Neither score constitutes medical, legal, or safety advice about any product.
Score Overview
| # | Dimension | Points | Core question |
|---|---|---|---|
| 1 | COA Visibility | 10 | Is batch-specific, third-party COA documentation linked from the product page before purchase? |
| 2 | Lab Panel Clarity | 10 | Does the COA show a full contaminant panel — potency, heavy metals, microbials, pesticides, and solvents? |
| 3 | Ingredient Transparency | 10 | Does the page clearly disclose all species, formats, extraction methods, and additives without proprietary blends? |
| 4 | Dosage Clarity | 10 | Are per-serving compound amounts, serving size, and frequency guidance clearly stated? |
| 5 | Medical Claim Restraint | 10 | Does the page avoid disease-treatment claims and evidence-overstating language? |
| 6 | Legal Disclaimers | 10 | Is the DSHEA disclaimer present, pregnancy caution included, and legal context presented accurately? |
| 7 | Support Availability | 10 | Can a consumer identify named leadership, reach support, and verify company identity? |
| 8 | Shipping Transparency | 10 | Are processing cutoff, carriers, free threshold, expedited pricing, and lost-order policy clearly stated? |
| 9 | Review Visibility | 10 | Is there a substantial independent third-party review footprint, including Trustpilot volume and BBB accreditation? |
| 10 | Refund/Replacement | 10 | Is there a dedicated policy page with a clear window, conditions, and return process? |
| Total | 100 |
Why Equal Weighting
Each of the ten dimensions addresses a distinct and non-substitutable consumer protection need. COA visibility cannot compensate for disease-treatment claims. Strong ingredient transparency cannot offset an inaccessible support channel. Every dimension is a necessary condition for a product page that enables truly informed consumer decision-making — not a tradeoff against other dimensions. Equal weighting reflects this structure.
Dimension 1: COA Visibility — 10 Points
Full Credit Requires:
- Named third-party laboratory
- Batch-specific Certificate of Analysis linked directly from the product page
- Testing date visible on the COA
- Product or batch identifier on the COA that matches the product currently being sold
- COA accessible before purchase without login, request, or barrier [1] Government Current Good Manufacturing Practice (CGMP) Regulations for Dietary Supplements Link →
Common Red Flags:
- “Lab tested” badge with no linked COA
- Generic COA not tied to a specific batch or lot number
- Missing lab name or accreditation
- COA with no date or date over one year old
- Screenshot of COA instead of verifiable document
- QR code that resolves to homepage rather than COA document
- COA requires a physical product scan or lot number entry with no alternative access path
Dimension 2: Lab Panel Clarity — 10 Points
Full Credit Requires:
- Named accredited third-party laboratory (ISO 17025 or equivalent)
- Potency or active compound panel appropriate to the product category
- Heavy metals panel (lead, arsenic, cadmium, mercury via ICP-MS)
- Microbial contamination panel (total aerobic plate count, yeast, mold, E. coli, Salmonella)
- Pesticide residues panel where relevant to growing conditions
- Residual solvents panel when extracts are used
Common Red Flags:
- Testing for potency only — no contaminant panels
- Heavy metals only — missing microbials, pesticides, or solvents
- In-house laboratory results presented as independent third-party verification
- Panel scope not publicly disclosed — “tested for quality and purity” without specifics
- Lab name absent from COA
Dimension 3: Ingredient Transparency — 10 Points
Full Credit Requires:
- Complete ingredient list visible on the product page before purchase
- Latin species name stated for every mushroom ingredient
- Fruiting body vs. mycelium clearly stated per species
- Extraction method stated (hot water, dual extraction, or none)
- Standardization amount stated where applicable (e.g., beta-glucan %)
- No proprietary blends that hide per-species or per-compound amounts when active category matters for safety
Common Red Flags:
- “Mushroom blend” without species names
- “Proprietary blend” used to conceal per-species dosing
- Fruiting body vs. mycelium distinction absent
- Latin names absent
- Mycelium-on-grain substrate undisclosed — stated mg per serving includes grain biomass, not active compound
- Full ingredient list only on physical label or post-purchase documentation
Dimension 4: Dosage Clarity — 10 Points
Full Credit Requires:
- Per-serving amount stated for each active compound in milligrams
- Serving size clearly defined
- Serving frequency or schedule guidance provided
- Where mycelium-on-grain is used, beta-glucan standardization % confirms actual active content per serving
Common Red Flags:
- Total blend mg stated with no per-compound breakdown
- Serving size undefined or ambiguous
- No frequency or schedule guidance
- Stated per-serving mg is substantially grain substrate (mycelium-on-grain) with no active compound standardization
Dimension 5: Medical Claim Restraint — 10 Points
Full Credit Requires:
- No disease-treatment claims (“treats,” “cures,” “prevents,” or “relieves” for diagnosed conditions)
- No claims to treat anxiety, depression, PTSD, addiction, chronic pain, ADHD, or other conditions
- Clear separation between clinical research and commercial product claims
- No “clinically proven” language without a specific citation applicable to the commercial product and formulation
- No guaranteed results language
- Visible professional consultation recommendation [2] Government Health Products Compliance Guidance Link →
Common Red Flags:
- “Treats depression” / “Cures anxiety” / “Replaces medication”
- “Clinically proven” without a citation applicable to the specific commercial product
- “Safe for everyone” / “No side effects”
- Citing full-dose supervised psilocybin therapy research to support a commercial microdose product
- “Natural” language used to minimize risk without substantive safety disclosure
Dimension 6: Legal Disclaimers — 10 Points
Full Credit Requires:
- Full DSHEA disclaimer on every product page: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”
- Pregnancy and breastfeeding caution visible on or adjacent to the product page
- No “100% legal” or “ships anywhere legally” without jurisdictional qualification
- No claim that decriminalization equals commercial legality [3] primary-legal 21 U.S.C. § 812 — Schedules of controlled substances Link → [4] Government Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) Link →
Common Red Flags:
- DSHEA disclaimer absent or only in fine print
- Pregnancy caution only on physical label or post-purchase insert
- “100% legal everywhere” without specifying compound, jurisdiction, and legal context
- “Legal in X cities” used to imply national commercial legality
- Australian or non-US consumer protection language cited in a US-facing policy without applicable US terms
Dimension 7: Support Availability — 10 Points
Full Credit Requires:
- Named individual leadership (CEO, founder, or director) publicly identified
- Phone number confirmed
- Email address confirmed
- Live chat or equivalent real-time support channel confirmed
- About page with company background
- Named physical location
Common Red Flags:
- No named leadership — anonymous company
- No phone number
- Email-only support with no phone or live chat
- Generic contact form as sole support channel
- No about page
- No named location or legal entity
Dimension 8: Shipping Transparency — 10 Points
Full Credit Requires:
- Processing cutoff time stated
- Named carriers confirmed
- Free shipping threshold stated
- Expedited shipping options with pricing stated
- Weekend shipping status clarified
- International shipping regions and rates stated
- Lost or missing order policy stated
Common Red Flags:
- “Free shipping” with no threshold, carrier, or processing cutoff
- No expedited options stated
- No lost-order policy
- International availability unclear
- Non-US consumer protection law (e.g., Australian law) cited as governing a US customer’s purchase
Dimension 9: Review Visibility — 10 Points
Full Credit Requires:
- Trustpilot profile with 500+ reviews (independent of company control)
- BBB accredited with confirmed A or A+ rating
- Google Business Profile confirmed
- Third-party review footprint independent of on-site review widgets
Common Red Flags:
- On-site review count high; independent Trustpilot count critically low (under 50)
- No Trustpilot profile at all
- No BBB accreditation
- Facility certification badge (BRCGS, GMP, FDA-registered) presented as a substitute for consumer-facing review visibility — these are independent variables
Dimension 10: Refund/Replacement — 10 Points
Full Credit Requires:
- Dedicated policy page (not only footer links)
- Clear return window stated — 30+ days for full credit
- Conditions for return clearly stated
- Return process described step-by-step
- Return shipping responsibility stated
- Subscription cancellation process clearly accessible
Common Red Flags:
- Return policy only in footer or buried in Terms of Service
- Return window under 30 days
- Restocking fees or photo requirements creating meaningful friction
- Subscription auto-enrollment without clear cancellation path
- Confirmed Trustpilot pattern of refund non-response or failed cancellations
Grade Ranges
| Score | Grade | Interpretation |
|---|---|---|
| 90–100 | A — High Transparency | Page clearly explains product, ingredients, testing, risks, legal context, and verification path across all ten dimensions |
| 75–89 | B — Strong Transparency | Most important information present; minor gaps in one or two dimensions |
| 60–74 | C — Partial Transparency | Notable gaps in testing documentation, ingredient disclosure, claims, safety, or accountability |
| 40–59 | D — Low Transparency | Heavy reliance on vague claims, incomplete testing, unclear ingredients, or limited company disclosure |
| Below 40 | F — Very Low Transparency | Does not provide enough information for a consumer to understand the product, contents, or risks |
Frequently Asked Questions
Does a high score mean a product is safe, effective, or legal?
No. The score measures how clearly a company communicates what a consumer needs to know. A transparent product page can still carry risks. A less transparent page is not automatically unsafe. This framework helps consumers identify what information is present or absent — not whether a product is medically appropriate, clinically effective, or lawful in their jurisdiction.
Why does each dimension receive equal weight?
Each of the ten dimensions addresses a distinct and non-substitutable consumer protection need. COA visibility cannot compensate for disease-treatment claims. Strong ingredient transparency cannot offset an inaccessible support channel. Equal weighting reflects the principle that every dimension is a necessary condition for meaningful transparency. [1] Government Current Good Manufacturing Practice (CGMP) Regulations for Dietary Supplements Link → A failure in any one dimension leaves a consumer without information they need.
Can a product page score full points in some dimensions and very low in others?
Yes. The dimensions are evaluated independently. A product page can provide excellent lab testing documentation (10/10) while making unacceptable disease-treatment claims (0/10). [2] Government Health Products Compliance Guidance Link → The total score is additive, but reviewing scores by dimension reveals where specific transparency failures exist and which gaps matter most for a given consumer’s decision.
What is the most common way brands lose points across all ten dimensions?
COA visibility and lab panel clarity are the dimensions with the most widespread point loss across the 2026 audit. The majority of audited entries either had no publicly linked COA, linked a generic or undated document, or limited testing to potency only without a full contaminant panel. Medical claim restraint and legal disclaimer completeness are the next most common failure areas.